Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017191147) COMBINATION THERAPY WITH CPG TLR9 LIGAND
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2017/191147 International Application No.: PCT/EP2017/060444
Publication Date: 09.11.2017 International Filing Date: 03.05.2017
IPC:
A61K 39/00 (2006.01) ,A61K 39/12 (2006.01) ,A61K 39/39 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
39
characterised by the immunostimulating additives, e.g. chemical adjuvants
Applicants:
TRANSGENE SA [FR/FR]; Parc d'innovation Boulevard Gonthier d'Andernach 67400 ILLKIRCH GRAFFENSTADEN, FR
OLIGOVAX [FR/FR]; 102 avenue des Champs Elysées 75008 PARIS, FR
Inventors:
RITTNER, Karola; FR
KRATZER, Roland; FR
CARPENTIER, Antoine; FR
Agent:
REGIMBEAU; 20, rue de Chazelles 75847 PARIS CEDEX 17, FR
Priority Data:
16305523.904.05.2016EP
Title (EN) COMBINATION THERAPY WITH CPG TLR9 LIGAND
(FR) POLYTHÉRAPIE AVEC UN LIGAND DE TLR9 CPG
Abstract:
(EN) The present invention generally relates to an immunostimulatory combination comprising a first composition comprising a therapeutic vaccine and a second composition comprising one or more TLR9 ligand(s) such as CpG-containing oligonucleotide(s) as well as the use of such a first composition in combination with said second composition for treating a subject in need thereof. A specific embodiment is directed to the combination of a vectorized therapeutic vaccine encoding antigen(s) and a CpG-containing oligonucleotide such as Litenimod. Embodiments also include kits comprising such compositions as well as methods for treating, preventing or inhibiting diseases, in particular proliferative diseases or infectious diseases comprising administration of such first and second compositions. The invention is of very special interest in the field of immunotherapy, specifically for enhancing host's innate immune response, modifying local cytokine and chemokine profile and leukocyte populations at or around the treatment site and/or at or around the site of infection.
(FR) La présente invention concerne de manière générale une association immunostimulante comprenant une première composition comprenant un vaccin thérapeutique et une seconde composition comprenant un ou plusieurs ligand(s) de TLR9 tel(s) que un ou des oligonucléotide(s) contenant CpG, ainsi que l'utilisation de ladite première composition en association avec ladite seconde composition pour traiter un sujet en ayant besoin. Un mode de réalisation spécifique concerne l'association d'un vaccin thérapeutique vectorisé codant pour un/des antigène(s) et d'un oligonucléotide contenant CpG tel que Litenimod. Des modes de réalisation comprennent également des kits comprenant lesdites compositions ainsi que des procédés permettant de traiter, prévenir ou inhiber des maladies, en particulier des maladies prolifératives ou des maladies infectieuses, consistant à administrer lesdites première et seconde compositions. L'invention présente un intérêt très spécifique dans le domaine de l'immunothérapie, en particulier pour améliorer la réponse immunitaire innée de l'hôte, en modifiant le profil local des cytokines et des chimiokines et les populations de leucocytes au niveau ou autour du site de traitement et/ou au niveau ou autour du site d'infection.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3023022EP3452081US20190134190